secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sage Therapeutics, Inc. (—)
CIK:        0001597553
Form:       8-K
Filed at:   2023-08-31T23:59:59+00:00
Accession:  0001193125-23-225406
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sage Therapeutics to cut ~40% of workforce, focus on zuranolone launch and SAGE-718/324
--------------------------------------------------------------------------------

- Workforce reduction of ~40%; expected severance charge of $36M-$38M in Q3 2023.
- Pipeline prioritization: focus on SAGE-718 and SAGE-324; earlier-stage programs paused.
- Planned commercial launch of ZURZUVAE (zuranolone) for postpartum depression in late 2023.
- Cash, equivalents, and marketable securities ~$1.0B as of June 30, 2023; expected to fund operations into 2026.
- Leadership team realigned to support pipeline and commercial priorities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1597553/000119312523225406/0001193125-23-225406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1597553/000119312523225406/d530485d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-225406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer